SAN DIEGO, Sept. 5, 2017 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today
announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate
presentation at Rodman & Renshaw's 19th Annual Global
Investment Conference. The conference is being held in
New York on September 10-12, 2017.
Details of the presentation are as follows:
•
|
Rodman &
Renshaw 19th Annual Global Investment Conference
|
|
Time/Date:
|
Tuesday, Sept.
12 at 10:50 - 11:15 AM ET
|
|
Location:
|
The Lotte New York
Palace Hotel, New York City
|
|
Room:
|
Kennedy I
|
To access the live webcast of the presentation, please visit
"Webcasts & Presentations" within the News & Events section
of Viking's Investors page at www.vikingtherapeutics.com.
Additionally, a replay of the webcast will be available on the
Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel, first-in-class or
best-in-class therapies for metabolic and endocrine
disorders. The company's research and development activities
leverage its expertise in metabolism to develop innovative
therapeutics designed to improve patients' lives. Viking has
exclusive worldwide rights to a portfolio of five therapeutic
programs in clinical trials or preclinical studies, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated. The company's clinical programs include VK5211,
an orally available, non-steroidal selective androgen receptor
modulator, or SARM, in Phase 2 development for the treatment and
prevention of lean body mass loss in patients who have undergone
hip fracture surgery, VK2809, a small molecule thyroid beta agonist
in Phase 2 development for hypercholesterolemia and non-alcoholic
fatty liver disease, and VK0612, a first-in-class, orally available
drug candidate in Phase 2 development for type 2 diabetes.
Viking is also developing novel and selective agonists of the
thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy,
as well as two earlier-stage programs targeting metabolic diseases
and anemia.
Follow Viking on Twitter @Viking_VKTX.
View original
content:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-rodman--renshaws-19th-annual-global-investment-conference-300513036.html
SOURCE Viking Therapeutics, Inc.